Notizie AIOM – anno XV n. 612
FDA Accepts sBLA and Grants Priority Review for Atezolizumab in Locally Advanced or Metastatic Urothelial Carcinoma
13 gennaio 2017 - On January 9, the U.S. Food and Drug Administration (FDA) accepted the supplemental Biologics License Application (sBLA) and granted Priority Review for atezolizumab in the treatment of patients with locally advanced or metastatic urothelial carcinoma who ...Leggi tutto
ASCO Releases Principles for Patient-Centered Health-Care Reform
12 gennaio 2017 - ASCO has released the “ASCO Principles for Patient-Centered Health-care Reform,” seven recommendations designed to ensure access to high-quality cancer care amid the changing U.S. health-care delivery landscape. The principles aim to assist ...Leggi tutto
Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer
Ipilimumab increases antitumor T-cell responses by binding to cytotoxic T-lymphocyte antigen 4. We evaluated treatment with ipilimumab in asymptomatic or minimally symptomatic patients with chemotherapy-naive metastatic castration-resistant prostate cancer without visceral ...Leggi tutto
Web-app
Una nuova web-app gratuita, in otto lingue, per computer, tablet e smartphone sul tumore al seno è disponibile sul sito del Corriere della Sera in collaborazione con l'Associazione Italiana di Oncologia Medica (leggi e scarica). Strumento interattivo in due versioni, ...Leggi tutto
ASCO Clinical Practice Guideline Update: Integration of Palliative Care Into Standard Oncology Care
9 gennaio 2017 - As reported by Betty R. Ferrell, PhD, of the City of Hope Medical Center, and colleagues in the Journal of Clinical Oncology, ASCO has released a clinical practice guideline update on the integration of palliative care into standard oncology care. This update ...Leggi tutto
Current Good Manufacturing Practice Requirements for Combination Products
Gennaio 2017 - This guidance describes and explains the final rule on CGMP requirements for combination products (final rule as codified in 21 CFR part 4) that FDA issued on January 22, 2013. Prior to issuance of the final rule, although CGMP regulations were in place to ...Leggi tutto
FDA Grants Priority Review to Frontline Pembrolizumab Combo for NSCLC
11 gennaio 2017 - The FDA has granted a priority review to a supplemental biologics license application (sBLA) for pembrolizumab (Keytruda) in combination with pemetrexed plus carboplatin as a treatment for patients with metastatic or advanced non-squamous non–small ...Leggi tutto
Second Opinions From Medical Oncologists for Early-Stage Breast CancerPrevalence, Correlates, and Consequences
Advances in the evaluation and treatment of breast cancer have made the clinical decision-making context much more complex. A second opinion from a medical oncologist may facilitate decision making for women with breast cancer, yet little is known about second opinion use. ...Leggi tutto